Patents Assigned to Celator Pharmaceuticals, Inc.
-
Patent number: 11787781Abstract: Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.Type: GrantFiled: May 7, 2021Date of Patent: October 17, 2023Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Daryl C. Drummond, Bolin Geng, Dmitri B. Kirpotin, Suresh K. Tipparaju, Alexander Koshkaryev, Ozan Alkan
-
Patent number: 11746386Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.Type: GrantFiled: February 11, 2021Date of Patent: September 5, 2023Assignees: CELATOR PHARMACEUTICALS, INC., OREGON HEALTH & SCIENCE UNIVERSITYInventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
-
Publication number: 20230059528Abstract: Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.Type: ApplicationFiled: July 15, 2022Publication date: February 23, 2023Applicant: Celator Pharmaceuticals, Inc.Inventors: Paul TARDI, Leon Wan, Shyam Madhusudan Garg, Jun Gao, Philippe Legros
-
Patent number: 11583544Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).Type: GrantFiled: December 24, 2019Date of Patent: February 21, 2023Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Mark E. Hayes, Charles O. Noble, Francis C. Szoka
-
Patent number: 11413253Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.Type: GrantFiled: September 4, 2020Date of Patent: August 16, 2022Assignee: Celator Pharmaceuticals, Inc.Inventors: Leon Wan, Winnie Lui, Paul Tardi, Lawrence Mayer
-
Publication number: 20210393665Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.Type: ApplicationFiled: June 3, 2021Publication date: December 23, 2021Applicant: Celator Pharmaceuticals, Inc.Inventors: Ronald CHEUNG, Stefan FADERL, Qi WANG
-
Publication number: 20210246512Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.Type: ApplicationFiled: February 11, 2021Publication date: August 12, 2021Applicants: Celator Pharmaceuticals, Inc., Oregon Health & Science UniversityInventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
-
Publication number: 20210169803Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: ApplicationFiled: November 13, 2020Publication date: June 10, 2021Applicant: Celator Pharmaceuticals, Inc.Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
-
Patent number: 11028076Abstract: Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.Type: GrantFiled: January 17, 2020Date of Patent: June 8, 2021Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Daryl C. Drummond, Bolin Geng, Dmitri B. Kirpotin, Suresh K. Tipparaju, Alexander Koshkaryev, Ozan Alkan
-
Publication number: 20210052508Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.Type: ApplicationFiled: September 4, 2020Publication date: February 25, 2021Applicant: Celator Pharmaceuticals, Inc.Inventors: Leon WAN, Winnie LUI, Paul TARDI, Lawrence MAYER
-
Patent number: 10927418Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.Type: GrantFiled: November 10, 2016Date of Patent: February 23, 2021Assignees: Celator Pharmaceuticals, Inc., Oreoon Health & Science UniversityInventors: Max Gordon, Paul Tardi, Jeffrey Tyner, Lawrence Mayer
-
Patent number: 10905775Abstract: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.Type: GrantFiled: May 29, 2013Date of Patent: February 2, 2021Assignees: Celator Pharmaceuticals, Inc., The Trustees of Princeton UniversityInventors: Lawrence D. Mayer, Robert K. Prud'homme, Christine J. Allen, Walid S. Saad
-
Patent number: 10835492Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: GrantFiled: November 5, 2018Date of Patent: November 17, 2020Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
-
Patent number: 10722464Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.Type: GrantFiled: July 27, 2018Date of Patent: July 28, 2020Assignee: Celator Pharmaceuticals, Inc.Inventors: Paul Tardi, Troy Harasym, Murray Webb, Clifford Shew, Andrew Janoff, Lawrence Mayer, Marcel Bally
-
Publication number: 20190209484Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.Type: ApplicationFiled: March 15, 2019Publication date: July 11, 2019Applicant: CELATOR PHARMACEUTICALS, INC.Inventors: Leon WAN, Winnie LUI, Paul TARDI, Lawrence MAYER
-
Patent number: 10285951Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.Type: GrantFiled: July 14, 2016Date of Patent: May 14, 2019Assignee: CELATOR PHARMACEUTICALS, INC.Inventors: Leon Wan, Winnie Lui, Paul Tardi, Lawrence Mayer
-
Publication number: 20190070112Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: ApplicationFiled: November 5, 2018Publication date: March 7, 2019Applicant: CELATOR PHARMACEUTICALS INC.Inventors: Donna CABRAL-LILLY, Lawrence MAYER, Paul TARDI, David WATKINS, Yi ZENG
-
Patent number: 10166184Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.Type: GrantFiled: February 7, 2018Date of Patent: January 1, 2019Assignee: CELATOR PHARMACEUTICALS INC.Inventors: Donna Cabral-Lilly, Lawrence Mayer, Paul Tardi, David Watkins, Yi Zeng
-
Publication number: 20180327854Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.Type: ApplicationFiled: November 10, 2016Publication date: November 15, 2018Applicants: Celator Pharmaceuticals Inc., OREGON HEALTH & SCIENCE UNIVERSITYInventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
-
Publication number: 20180271787Abstract: Compositions which comprise a liposomal camptothecin and optionally liposomal fluoropyrimidine and a targeted antitumor agent are useful in achieving enhanced therapeutic effects when combinations of these agents are administered.Type: ApplicationFiled: May 25, 2018Publication date: September 27, 2018Applicant: CELATOR PHARMACEUTICALS, INC.Inventors: Paul TARDI, Lawrence MAYER, David BERMUDES